tbuckley/cabot-search huggingface dataset:
Abstract 533: Critical role of MMP-9 dimers in cell migration: design of inhibitory peptides
Authors: Antoine Dufour, Nicole S. Sampson, Cem Kuscu, Stanley Zucker, Jian Cao
Journal: Cancer Research (2010)

Abstract Non-proteolytic activities of matrix metalloproteinases (MMPs) have recently been shown to impact cell migration, but the precise mechanism remains to be understood. We previously demonstrated that the hemopexin (PEX) domain of MMP-9 is a prerequisite for enhanced cell migration. Using a biochemical approach, we now report that dimerization of MMP-9 through the PEX domain is necessary for MMP-9-enhanced cell migration. Following a series of substitution mutations within the MMP-9 PEX domain, two critical motifs in the outermost strands of the first and fourth blades of MMP-9 PEX domain were found to be involved in MMP-9 homo- and hetero- dimer formations. Peptides mimicking these motifs efficiently blocked MMP-9 dimer formations and inhibited MMP-9-mediated cell migration, but not membrane type 1- MMP (MT1-MMP)-induced cell migration. In addition, these peptides demonstrate inhibitory effects on migration of human fibrosarcoma HT1080 cells, which express high level of endogenous MMP-9. Using a shRNA approach, CD44 was found to be a critical molecule in MMP-9-mediated cell migration. Furthermore, a novel axis involving an MMP-9-CD44-EGFR signaling pathway in cell migration was identified using antibody microarray analysis and specific receptor tyrosine kinase inhibitors. In conclusion, we dissected the mechanism of proMMP-9-enhanced cell migration and developed structure-based inhibitory peptides specific targeting of MMP-9-mediated cell migration. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 533.
Abstract 1393: CD44v3-positive (CD44v3+) and CD24-negative (CD24−) cells possess cancer stem cell (CSC)-like properties in a human oral squamous cell carcinoma cell line
Authors: Keita Todoroki, Sachiko Ogasawara, Jun Akiba, Masamichi Nakayama, Yoshiki Naito, Jingo Kusukawa, Hirohisa Yano
Journal: Cancer Research (2015)

Abstract Background: CSCs are defined as minor cell population which have higher tumor-initiating ability, self-renewal ability and multilineage potential. Although CSCs in oral squamous cell carcinoma (OSCC) were identified by several surface antigen (e.g., CD44, CD133) or ALDEFLOUR assay, it is still elusive which are universal markers for CSC in OSCC. The aim of this study is to clarify potential CSC markers for a OSCC cell line using a combination of cell surface markers, CD44v3 and CD24. Materials and Methods: A OSCC cell line, SAS, was used in the experiment. CD44v3+/CD24− cell fraction was sorted from SAS cells with a FACSAria II and compared with the other three fractions (CD44v3+/CD24+, CD44v3− /CD24−, CD44v3−/CD24+ cell fraction) in cell proliferation, drug resistance and sphere forming ability. mRNA expression levels of various genes, such as stemness genes, anti-apoptosis genes and hypoxia-related genes, were compared among the fractions using quantitative real-time reverse transcriptase-polymerase chain reaction. Results: The proportion of CD44v3+/CD24−, CD44v3+/CD24+, CD44v3−/CD24−, CD44v3−/CD24+ cells was 34.9%, 39.8%, 14.2% and 11.0%, respectively. CD44v3+/CD24− cells showed a higher sphere forming ability, and drug resistance for CDDP, 5-FU and Cetuximab and expressed higher mRNA levels of CSC property-related genes (ABCG2, Oct-4, Nanog) and a hypoxia-related gene (HIF-1α) than the other cell fractions. There were no significant differences in cell proliferation among the fractions. Conclusion: The results suggest that CD44v3+/CD24− cell fractions in SAS possess CSC-like properties. The investigation of tumorigenic capacity in NOD/SCID mice is now under way. Citation Format: Keita Todoroki, Sachiko Ogasawara, Jun Akiba, Masamichi Nakayama, Yoshiki Naito, Jingo Kusukawa, Hirohisa Yano. CD44v3-positive (CD44v3+) and CD24-negative (CD24−) cells possess cancer stem cell (CSC)-like properties in a human oral squamous cell carcinoma cell line. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1393. doi:10.1158/1538-7445.AM2015-1393
SP0004 Gain to society from rheumatoid arthritis treatment: Data from randomized trials
Authors: A. Kavanaugh
Journal: Annals of the Rheumatic Diseases (2013)

Rheumatoid Arthritis (RA), a chronic progressive systemic inflammatory disorder, can exert a tremendous toll from affected persons in terms of impaired functional status, and accelerated morbidity and mortality. The uncontrolled inflammation of RA is associated with substantial economic costs, not only for patients and their families, but also to society. The costs can be broadly divided into: 1) direct costs (including costs for medications, hospitalizations, physician/clinic visits, laboratory and other tests for monitoring therapy, and the costs of diagnosing and treating adverse effects) and 2) indirect costs (including opportunity costs, such as lost wages and impaired productivity at work and at home; failure costs, such as the direct and indirect costs for alternative treatments; and intangible costs, to the patient and family). In recent years, the introduction of novel therapies, particularly biologic agents, as well as newer treatment paradigms, have allowed clinicians to more optimally treat their RA patients. RA patients are more likely to achieve lower disease activity and better outcomes, such as improved functional status. Such improvements decrease the indirect costs of RA, and hence may balance costs related to treatment. Due to increasing health care costs worldwide, there has been interest in assessing the value of medical therapies. In RA, a large number of pharmacoeconomic assessments have been performed, including assessments of data from randomized clinical trials. There are both advantages as well as limitations to using data from clinical trials for pharmacoeconomic assessments. Overall, data from clinical trials provide support for the conclusion that in patients with severe active RA, highly effective interventions, including the use of biologic agents, can have an incremental cost efficacy within the accepted range for medical interventions. <h3>References</h3> Ter Wee MM, et al. Ann Rheum Dis 2012;71:161-71. Verstappen SMM, et al. Rheumatology 2012;51:216-29. Wolfe F et al. Rheumatology 2004;43:4-6. Maetzel A. A&amp;R (AC&amp;R) 2005;53:3-4. Solomon D, Maetzel A. Int J Adv Rheumatol 2004;2:91-6. Wong J. Clin Exp Rheumatol 2004;22(Suppl 35):S65-70. <h3>Disclosure of Interest</h3> A. Kavanaugh Grant/Research support from: amgen, abbott, ucb, bms, janssen, roche
A validation of the use of names to screen for risk of chronic hepatitis B in Victoria, Australia, 2001 to 2010
Authors: J H MacLachlan, Y J Wang, B C Cowie
Journal: Eurosurveillance (2013)

The burden of chronic hepatitis B (CHB) is increasing in Australia, particularly in those born in the Asia-Pacific region, and nearly half are undiagnosed. Primary care clinicians have a key role in diagnosing CHB, however identification of patients at risk is hindered by lack of awareness and limited information on country of birth in patient records. This study evaluates the potential of a validated list of names associated with Asian country of birth as a screening tool to predict risk of CHB, by comparing it with surveillance records for all people diagnosed with CHB or salmonellosis in Victoria from 2001 to 2010, and analysed using standard screening tools. Name list match was associated with CHB notification, with over 60% of cases having one name matching the list (sensitivity), and nearly one third matching both given name and surname; less than 15% and 2% of salmonellosis notifications matched for one name and both names, respectively (false positives). These results show that more than half of notified cases of CHB would have been identified by this name list, and that it could be used in support of initiatives to improve diagnosis of patients with diseases associated with country of birth when limited information is available.
OC-009 A Multicentre Retrospective Comparison Of Plastic, Uncovered And Fully Covered Metal Stents In The Management Of Distal Malignant Biliary Strictures
Authors: JE Elias, F Sampaziotis, WJ Griffiths, AL King, B Macfarlane, JM Woodward, GD Corbett, A Leahy
Journal: Gut (2014)

<h3>Introduction</h3> Uncovered self-expanding metal stents (USEMS) remain patent longer than plastic stents (PS) in patients with malignant bile duct strictures (MBDS). However, their difficult removal can compromise surgical tumour resection and so, prior to tumour staging a PS is commonly used. A solution may be offered by metal stents which have been coated with plastic, making them easier to remove. Our preliminary data analysis <sup>[1]</sup> suggested that fully covered self-expanding metal stents (FCSEMS) used as first line management of MBDS result in a longer patency time and similar complication rates compared to USEMS and PS. We now present data from an expanded database of patients to provide further evidence of the efficacy of FCSEMS in this situation. <h3>Methods</h3> A multicentre retrospective study was conducted of patients with MBDS who underwent ERCP and primary stenting with PS, USEMS or FCSEMS between 2007 and 2013. Data was collected from patient records on age, cancer type, stent patency time, complications and survival. Patency time was calculated as the period between stent insertion and occlusion, death or resection with a patent stent. Patients who underwent resection were excluded from the patient survival analysis. Statistical analysis used Kaplan Meier and Log Rank tests for patency and survival and Fisher’s exact test for complications. The software used was IBM SPSS Statistics 20. <h3>Results</h3> 268 patients were included. FCSEMS (n = 41) remained patent for a mean of 292 days versus 150 days for USEMS (n = 89) (p &lt; 0.001) and 68 days for PS (n = 138) (p &lt; 0.001). FCSEMS also resulted in a statistically significant improvement in patient survival with a mean of 297 days versus 191 days for USEMS (p &lt; 0.001) and 216 days for PS (p = 0.001). Both FCSEMS and USEMS produced a significantly lower incidence of cholangitis than PS (p &lt; 0.047 and &lt;0.013 respectively). There were 2 episodes of pancreatitis in the FCSEMS group (4.9%) compared to 3 in the PS group (2.2%) and 1 in the USEMS group (1.1%) but this was not statistically significant. <h3>Conclusion</h3> For primary stenting of MBDS, FCSEMS result in a longer patency time and a reduced incidence of cholangitis compared to PS. Combined with evidence supporting their ease of operative removal, this data suggests FCSEMS may be the superior option for primary stenting of MBDS. However, a larger cohort will be required to clarify the significance of the increased risk of pancreatitis observed in the FCSEMS group. <h3>Reference</h3> 1 Sampaziotis <i>et al</i>. A retrospective comparison of plastic, uncovered and fully covered metal stents in the management of distal malignant biliary strictures. <i>BSG Abstract</i> 13–1209 <h3>Disclosure of Interest</h3> None Declared.
Abstract 5252: Utilization of TumorGraft technology for personalized breast cancer treatment
Authors: Meredith James, Ronnie Morris, Elizabeth Bruckheimer, Eric Rowinsky, Sarah Bacus, David Sidransky, Keren Paz
Journal: Cancer Research (2012)

Abstract Breast cancer is the most common cancer among women with over 280,000 new annual cases and 40,000 deaths in the US alone. While hormonal-dependent breast cancer is correlated with good prognosis, an adequate solution for hormonal-independent tumors remains an unmet medical need, largely due to a significant heterogeneity within tumors and their makeover. Various personalized oncology approaches aim at tailoring the optimal regimen for these patients by better understanding their tumor distinctiveness. Champions Oncology focuses on personalizing cancer treatment through the generation of TumorGraft™ models form the patient's own tumor. The current study is focused on the attempt to identify a personalized solution for a patient with HER2-amplified metastatic breast cancer whose disease progressed on Trastuzimab (Herceptin). Using Champions novel and cutting-edge TumorGraft™ technology, the challenge was confronted empirically by preforming a personalized clinical trial in vivo. Tumor fragments, obtained from both the primary breast tumor and lung metastasis, were implanted in immune-deficient mice in a manner that preserves the biological properties of the original tumor and its supporting stroma. Once the TumorGraft™ models were established, panel of drugs and drug combinations were evaluated to help identify treatment regimens that are likely to be most effective for the patient clinically. The drug study encompassed 7 different treatment groups including FDA-approved, as well as investigational agents. Of the 7 treatment arms, 3 demonstrated a significant anti-tumor response with tumor growth inhibition values of 80, 93 and 97% for Lapatinib+Capecitabine, Gemcitabine+Carboplatin and Ixabepilone+Capecitabine, respectively. Molecular analysis of the tumor revealed a truncated HER2 (p95) and a robust HER2 translocation to the nucleus. Additional molecular characterization is ongoing to determine other potential signatures of response. Results from the TumorGraft™ study were recommended to the patient and her medical oncologist and new lines of treatment were commenced subsequently. Herein, we describe the data from the TumorGraft™ drug study, the molecular exploration and the pathway analysis of the primary and the metastatic tumor and the consequences correlation to the clinical outcome. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5252. doi:1538-7445.AM2012-5252
Risk of Hemolytic Uremic Syndrome From Antibiotic Treatment of<i>Escherichia coli</i>O157:H7 Colitis
Authors: Phillip I. Tarr, Sandra L. Watkins, Marguerite A. Neill
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An Outbreak of Sporotrichosis in Vermont Associated with Sphagnum Moss as the Source of Infection
Authors: D. J. D'Alessio, L. J. Leavens, G. B. Strumpf, C. D. Smith
Journal: New England Journal of Medicine (1965)

SPOROTRICHUM SCHENCKII has been recovered from many types of plants and several kinds of domestic animals as well as from soil.1 , 2 In 1926 Foerster3 reviewed the American literature on sporotrichosis and reported 18 new cases, 14 of which were in nursery workers. The thorns of the barberry shrub were incriminated as the source of infection in 10 of these patients. Of 148 reported cases 84 were in males, 50 per cent of whom worked in either gardening or agriculture; 130 of the cases occurred in the Mississippi River basin. From this, Foerster concluded that sporotrichosis is an occupational disease in . . .
BM-05 * IPILUMUMAB THERAPY FOR MELANOMA BRAIN METASTASES IS ASSOCIATED WITH INCREASED RADIATION NECROSIS
Authors: G. Barkhoudarian, G. Deutsch, S. Yost, H. Duong, C. Chaloner, A. Eisenberg, P. Boasberg, M. Faries, O. Hamid, D. Kelly
Journal: Neuro-Oncology (2014)

BACKGROUND: Melanoma brain metastases (MBMs) are typically associated with poor prognosis, requiring combination therapy with surgery and radiation. The CTLA-4 antagonist, ipilumumab, has shown improved survival in patients with MBMs. Herein, we present a series of patients treated with variable combinations of radiation, surgery and ipilumumab. METHODS: Over 4.5 years, all patients with symptomatic MBMs with at least one craniotomy for tumor resection and radiation therapy were included. The onset, duration and magnitude of radiation necrosis (RN) were analyzed relative to surgical resection, tumor size, and ipilumumab therapy. RN was based on pathology or imaging findings. Patients with less than 6 months follow-up were excluded. RESULTS: The cohort consisted of 59 patients (42 males,17 females,age 58 ± 14 years) with 154 metastatic tumors. 48 patients (81.4%) underwent adjuvant radiation therapy (74.6% SRS,22% WBRT). A total of 68 MBMs were resected in these patients (27.3 ± 11.6mm max dimension). Median overall and progression-free survival was 10.5 and 6.8 months respectively. 72% received ipilumumab therapy. Lesions receiving both SRS and WBRT had increased risk of RN compared to SRS or WBRT alone (38.5%v13.1%v9.1%,p = 0.003). Ipilumumab therapy was associated with increased RN (20.7%v4.7%,p = 0.015). Lesions that received ipilumumab following radiation were at higher risk of developing RN compared to ipilumumab preceding radiation (26.0%v16.4%,p = 0.023) with treatment interval 2.5v3.8 months. Overall, there was no significant difference in tumor size and rate of RN (28.2 ± 11.8v22.7 ± 12.2mm,p = 0.071). However, in patients who did not receive ipilumumab therapy, tumor size was significantly associated with RN (28.2 ± 11.8v19.2 ± 9.1mm,p = 0.010). Multivariate analysis demonstrated SRS in the absence of ipilumumab as an independent factor for RN. Surgical resection prior to radiation did not reduce RN rate (15.9%v23.7%,p = 0.312). CONCLUSION: This series demonstrates that ipilumumab independently increases the risk of RN for MBMs, particularly with SRS. Paradoxically, ipilumumab therapy following radiation had a higher rate of RN, suggesting an ongoing immune-mediated process in the radiated field.
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
Authors: Hervé Decousus, Alain Leizorovicz, Florence Parent, Yves Page, Bernard Tardy, Philippe Girard, Silvy Laporte, René Faivre, Bernard Charbonnier, Fabrice-Guy Barral, Yann Huet, Gérald Simonneau
Journal: New England Journal of Medicine (1998)

The efficacy and safety of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis are still a matter of debate.
PTU-036 Mycophenolate mofetil in patients with autoimmune hepatitis and azathioprine intolerance: histological response compared to that in azathioprine-treated patients
Authors: H Dhaliwal, E McFarlane, A K Dube, D Gleeson, M Karajeh
Journal: Gut (2012)

<h3>Introduction</h3> Prednisolone (PRED) in combination with azathioprine (AZA) is commonly used to induce remission in autoimmune hepatitis (AIH). Up to 20% of patients are intolerant of AZA and mycophenolate mofetil (MMF) is often used as an alternative. However there are few data on its ability to induce histological remission and prevent relapse. Therefore, we aimed to evaluate the efficacy of MMF, compared to AZA, in inducing and maintaining remission. <h3>Methods</h3> 58 patients with AIH presenting since 2003 were retrospectively studied. All initially received PRED+AZA. Those who developed intolerance to AZA (n=13, after 1–6 weeks) were switched to MMF (1 (1–2) g/day). Follow-up liver biopsy, obtained after median 25 (12–41) months was assessed in 11 of these patients (MMF group) and 44 patients in whom AZA was continued (AZA group). <h3>Results</h3> The two groups were similar with regards to (a) serum ALT at 0, 3, 6, 12, 24 and 36 months, and (b) Ishak necroinflammatory grade at baseline (11 vs 10 in AZA and MMF group respectively, p=0.6) and follow-up (4 vs 3, p=0.9) biopsy. 48% of the AZA group and 64% of the MMF group achieved histological remission (p=0.3). Fibrosis regressed in both groups but regression was greater in the MMF group (Ishak stage 3.2 to 1.7, p=0.002) compared to the AZA group (3.3 to 2.8, p=0.02). When attempted, PRED was successfully withdrawn in 7/10 patients in the MMF group, and in 32/37 patients in the AZA group (p=0.3). After PRED withdrawal, 4/7 patients in the MMF group and 11/32 patients in the AZA group relapsed (p=0.4). Up to the end of follow-up (71 months for AZA vs 65 months for MMF, p=0.6) PRED requirement (median 0 vs 2.5 mg, p=0.8) and relapse rate (median 0 vs 0, p=0.5) were similar in the two groups. <h3>Conclusion</h3> MMF is as effective as AZA, at inducing and maintaining biochemical and histological remission in AIH. It may lead to more regression of fibrosis but this requires further evaluation. <h3>Competing interests</h3> None declared.
Committee Debates Use of Army Breast Cancer Funds
Authors: N. S. Larsen
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Committee Debates Use of Army Breast Cancer Funds Get access Natalie S. Larsen Natalie S. Larsen Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 6, 17 March 1993, Pages 430–431, https://doi.org/10.1093/jnci/85.6.430-a Published: 17 March 1993
TCT-148 Blood Transfusion And The Risk Of Acute Kidney Injury Following Transcatheter Aortic Valve Implantation
Authors: Rutger-Jan Nuis, Josep Rodes-Cabau, Jan Malte Sinning, Leen van Garsse, Joelle Kefer, Johan Bosmans, Antonio Dager, Nicolas Van Mieghem, Marina Urena, Nikos Werner, Georg Nickenig, Jos Maessen, Parla Astarci, Luis Benitez, Eric Dumont, Ron Van Domburg, Peter De Jaegere
Journal: Journal of the American College of Cardiology (2012)
P191 HEPATITIS B AND C VIRUS PROMOTE CROSSTALK BETWEEN HYPOXIA AND GLUCOCORTICOID SIGNALLING PATHWAYS TO RE-PROGRAMME HEPATOCYTE METABOLISM AND TO EVADE HOST INTERFERONS
Authors: G.K. Wilson, L.W. Meredith, D. Greenland, L. Mailly, D. Tennant, M. Ashcroft, T.F. Baumert, J.W. Tomlinson, S.G. Hubscher, F.V. Eeden, P. Balfe, J.A. McKeating
Journal: Journal of Hepatology (2014)